Literature DB >> 25406628

Pseudomonas aeruginosa induced lung injury model.

Varsha Suresh Kumar1, Ruxana T Sadikot2, Jeanette E Purcell3, Asrar B Malik1, Yuru Liu4.   

Abstract

In order to study human acute lung injury and pneumonia, it is important to develop animal models to mimic various pathological features of this disease. Here we have developed a mouse lung injury model by intra-tracheal injection of bacteria Pseudomonas aeruginosa (P. aeruginosa or PA). Using this model, we were able to show lung inflammation at the early phase of injury. In addition, alveolar epithelial barrier leakiness was observed by analyzing bronchoalveolar lavage (BAL); and alveolar cell death was observed by Tunel assay using tissue prepared from injured lungs. At a later phase following injury, we observed cell proliferation required for the repair process. The injury was resolved 7 days from the initiation of P. aeruginosa injection. This model mimics the sequential course of lung inflammation, injury and repair during pneumonia. This clinically relevant animal model is suitable for studying pathology, mechanism of repair, following acute lung injury, and also can be used to test potential therapeutic agents for this disease.

Entities:  

Mesh:

Year:  2014        PMID: 25406628      PMCID: PMC4330790          DOI: 10.3791/52044

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  14 in total

Review 1.  The acute respiratory distress syndrome.

Authors:  L B Ware; M A Matthay
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia.

Authors:  K Kurahashi; O Kajikawa; T Sawa; M Ohara; M A Gropper; D W Frank; T R Martin; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Sepsis induces early alterations in innate immunity that impact mortality to secondary infection.

Authors:  Matthew J Delano; Terri Thayer; Sonia Gabrilovich; Kindra M Kelly-Scumpia; Robert D Winfield; Philip O Scumpia; Alex G Cuenca; Elizabeth Warner; Shannon M Wallet; Mark A Wallet; Kerri A O'Malley; Reuben Ramphal; Michael Clare-Salzer; Philip A Efron; Clayton E Mathews; Lyle L Moldawer
Journal:  J Immunol       Date:  2010-11-24       Impact factor: 5.422

Review 4.  Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.

Authors:  Ruxana T Sadikot; Timothy S Blackwell; John W Christman; Alice S Prince
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

5.  Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa.

Authors:  Ruxana T Sadikot; Heng Zeng; Myungsoo Joo; M Brett Everhart; Taylor P Sherrill; Bo Li; Dong-sheng Cheng; Fiona E Yull; John W Christman; Timothy S Blackwell
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

Review 6.  The role of chemokines in neutrophil biology.

Authors:  Yoshiro Kobayashi
Journal:  Front Biosci       Date:  2008-01-01

7.  Dynamin 2 and c-Abl are novel regulators of hyperoxia-mediated NADPH oxidase activation and reactive oxygen species production in caveolin-enriched microdomains of the endothelium.

Authors:  Patrick A Singleton; Srikanth Pendyala; Irina A Gorshkova; Nurbek Mambetsariev; Jaideep Moitra; Joe G N Garcia; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

Review 8.  Injury and repair in lung and airways.

Authors:  David W Shimabukuro; Teiji Sawa; Michael A Gropper
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

9.  A murine model of sepsis following smoke inhalation injury.

Authors:  Matthias Lange; Atsumori Hamahata; Daniel L Traber; Aimalohi Esechie; Collette Jonkam; Kamna Bansal; Yoshimitsu Nakano; Lillian D Traber; Perenlei Enkhbaatar
Journal:  Biochem Biophys Res Commun       Date:  2009-12-28       Impact factor: 3.575

Review 10.  Animal models of acute lung injury.

Authors:  Gustavo Matute-Bello; Charles W Frevert; Thomas R Martin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

View more
  5 in total

1.  Blockade of equilibrative nucleoside transporter 1/2 protects against Pseudomonas aeruginosa-induced acute lung injury and NLRP3 inflammasome activation.

Authors:  Eboni D Chambers; Alexis White; Alexander Vang; Zhengke Wang; Alfred Ayala; Tingting Weng; Michael Blackburn; Gaurav Choudhary; Sharon Rounds; Qing Lu
Journal:  FASEB J       Date:  2019-12-02       Impact factor: 5.191

2.  Intense light-elicited alveolar type 2-specific circadian PER2 protects from bacterial lung injury via BPIFB1.

Authors:  Yoshimasa Oyama; Sydney R Shuff; Nana Burns; Christine U Vohwinkel; Tobias Eckle
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-03-10       Impact factor: 6.011

3.  Dlk1-Mediated Temporal Regulation of Notch Signaling Is Required for Differentiation of Alveolar Type II to Type I Cells during Repair.

Authors:  Johanna Finn; Kilian Sottoriva; Kostandin V Pajcini; Jan K Kitajewski; Chang Chen; Wei Zhang; Asrar B Malik; Yuru Liu
Journal:  Cell Rep       Date:  2019-03-12       Impact factor: 9.423

4.  Genetic deletion of Sphk2 confers protection against Pseudomonas aeruginosa mediated differential expression of genes related to virulent infection and inflammation in mouse lung.

Authors:  David L Ebenezer; Panfeng Fu; Yashaswin Krishnan; Mark Maienschein-Cline; Hong Hu; Segun Jung; Ravi Madduri; Zarema Arbieva; Anantha Harijith; Viswanathan Natarajan
Journal:  BMC Genomics       Date:  2019-12-16       Impact factor: 3.969

5.  Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury.

Authors:  Kurt Bachmaier; Andrew Stuart; Abhalaxmi Singh; Amitabha Mukhopadhyay; Sreeparna Chakraborty; Zhigang Hong; Li Wang; Yoshikazu Tsukasaki; Mark Maienschein-Cline; Balaji B Ganesh; Prasad Kanteti; Jalees Rehman; Asrar B Malik
Journal:  ACS Nano       Date:  2022-03-01       Impact factor: 15.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.